Anzeige
Mehr »
Login
Montag, 08.07.2024 Börsentäglich über 12.000 News von 684 internationalen Medien
Neuer Börsen-Bulle: Unentdeckter Börsenstar mit sensationeller News und spottbilliger Bewertung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PZ7S | ISIN: FR0013481835 | Ticker-Symbol: 7V91
Frankfurt
08.07.24
09:09 Uhr
0,155 Euro
-0,008
-4,67 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
KLEA HOLDING Chart 1 Jahr
5-Tage-Chart
KLEA HOLDING 5-Tage-Chart
RealtimeGeldBriefZeit
0,1700,17316:06
Actusnews Wire
265 Leser
Artikel bewerten:
(1)

VISIOMED GROUP: Visiomed Group's Smart Salem launches new services and anticipates another quarter of significant growth

  • New blood testing packages launched in May
  • Launch of vaccinations and occupational health for beauticians
  • 58% revenue growth for the Wellness activity in May from April
  • Additional services to be launched in June

Paris, Dubai, June 17, 2024

VISIOMED GROUP (FR0013481835 - ALVMG), a group dedicated to innovative healthcare technologies and services, shares key updates on the recent activities of its subsidiary Smart Salem for the months of May and June.

  • Smart Salem launched a number of new services in May including new blood testing packages (of which female hormone testing) and new vaccination services
  • The company also successfully launched its first occupational health offer for beauticians and salon workers - these medical tests are mandatory for workers in certain sectors as per new regulation recently launched in 2024
  • The wellness activity is seeing strong month-on-month growth with revenue growing by 58% in May in comparison to April
  • Additional new services will be launched in June including dietician consultations, gut health testing and Electrocardiogram (ECG) screening

Following the end of the month of June, Visiomed will release Smart Salem's key financials for the second quarter of the year, which are again excellent and in line with our expectations.

***

About VISIOMED GROUP

Founded in 2007, VISIOMED GROUP relies on a long experience in the health sector to invest in innovative health technologies and services in France and abroad.

The Group now has focused its activities on the Middle East since 2021 and the acquisition of Smart Salem, the first digital medical analysis centre accredited by the Dubai Health Authority (DHA) in the United Arab Emirates, 100% owned by Visiomed Group.

Visiomed is also accelerating its development in the region with the creation of Smart Health, a joint venture that will lead the deployment of the Group's innovative centres in Saudi Arabia.

Based in Paris, Visiomed Group is listed on Euronext Growth (ALVMG). For more information, visit www.visiomed-group.com

CONTACTS

Jérôme FABREGUETTES LEIBFatou-Kiné N'DIAYE
Investor RelationsFinancial Press Relations
visiomed@actus.frfndiaye@actus.fr
Phone: +33 1 53 67 36 78Phone: +33 1 53 67 36 75

© Visiomed Group SA 2024. The brands mentioned are the property of their respective authors. Reproduction prohibited, even partial, without prior authorization.

------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: nWlvkp2YZ2ecnpxtaMmZbJWXZploxZTFZWqemWRwlJeWm3GWmptiasrKZnFnl25v
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-86299-alvmg-cp-smartsalem-eng_vdef.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2024 Actusnews Wire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.